Production and In Vitro Characterization of Solid Dosage form Incorporating Drug Nanoparticles

被引:64
作者
Basa, Shradhanjali [2 ]
Muniyappan, Thilekkumar [1 ]
Karatgi, Pradeep [1 ]
Prabhu, Raghavendra [1 ]
Pillai, Ravi [1 ]
机构
[1] Dr Reddys Labs Ltd, NCE & CPS Prod Dev, Integrated Prod Dev, Hyderabad 500072, Andhra Pradesh, India
[2] Annamalai Univ, Dept Pharm, Chidambaram, India
关键词
nanosuspension; poorly soluble drugs; particle size; ketoconazole; dissolution;
D O I
10.1080/03639040802005024
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The objective of this study was to develop a tablet formulation of ketoconazole incorporating drug nanoparticles to enhance saturation solubility and dissolution velocity for enhancing bioavailability and reducing variability in systemic exposure. The bioavailability of ketoconazole is dissolution limited following oral administration. To enhance bioavailability and overcome variability in systemic exposure, a nanoparticle formulation of ketoconazole was developed. Ketoconazole nanoparticles were prepared using a media-milling technique. The nanosuspension was layered onto water-soluble carriers using a fluid bed processor. The nanosuspensions were characterized for particle size before and after layering onto water-soluble carriers. The saturation solubility and dissolution characteristics were investigated and compared with commercial ketoconazole formulation to ascertain the impact of particle size on drug dissolution. The drug nanoparticles were evaluated for solid-state transitions before and after milling using differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD). This study demonstrated that tablet formulation incorporating ketoconazole nanoparticles showed significantly faster rate of drug dissolution in a discriminating dissolution medium as compared with commercially available tablet formulation. There was no affect on solid-state properties of ketoconazole following milling. The manufacturing process used is relatively simple and scalable indicating general applicability to enhance dissolution and bioavailability of many sparingly soluble compounds.
引用
收藏
页码:1209 / 1218
页数:10
相关论文
共 28 条
[1]  
[Anonymous], EMULSIONS NANOSUSPEN, DOI DOI 10.1002/jps.10590
[2]   Current industrial practices of assessing permeability and P-glycoprotein interaction [J].
Balimane, PV ;
Han, YH ;
Chong, SH .
AAPS JOURNAL, 2006, 8 (01) :E1-E13
[3]   PHARMACEUTICAL SOLIDS - A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS [J].
BYRN, S ;
PFEIFFER, R ;
GANEY, M ;
HOIBERG, C ;
POOCHIKIAN, G .
PHARMACEUTICAL RESEARCH, 1995, 12 (07) :945-954
[4]   EFFECT OF PH ON DISINTEGRATION AND DISSOLUTION OF KETOCONAZOLE TABLETS [J].
CARLSON, JA ;
MANN, HJ ;
CANAFAX, DM .
AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1983, 40 (08) :1334-1336
[5]  
Connors R.D., 2004, DRUG DELIV TECHNOL, V4, P78
[6]   Preparation and evaluation of ketoconazole-beta-cyclodextrin multicomponent complexes [J].
EsclusaDiaz, MT ;
GayoOtero, M ;
PerezMarcos, MB ;
VilaJato, JL ;
TorresLabandeira, JJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 142 (02) :183-187
[7]   Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs [J].
Galia, E ;
Nicolaides, E ;
Hörter, D ;
Löbenberg, R ;
Reppas, C ;
Dressman, JB .
PHARMACEUTICAL RESEARCH, 1998, 15 (05) :698-705
[8]   Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base [J].
Hecq, J. ;
Deleers, M. ;
Fanara, D. ;
Vranckx, H. ;
Boulanger, P. ;
Le Lamer, S. ;
Amighi, K. .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2006, 64 (03) :360-368
[9]   Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine [J].
Hecq, J ;
Deleers, M ;
Fanara, D ;
Vranckx, H ;
Amighi, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 299 (1-2) :167-177
[10]   Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide [J].
Jacobs, C ;
Kayser, O ;
Müller, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 196 (02) :161-164